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Abstract
The type VI secretion system (T6SS) is a secretion pathway widespread in Gram-negative
bacteria that targets toxins in both prokaryotic and eukaryotic cells. Although most T6SSs
identified so far are involved in inter-bacterial competition, a few are directly required for full
virulence of pathogens. The T6SS comprises 13 core proteins that assemble a large com-
plex structurally and functionally similar to a phage contractile tail structure anchored to the
cell envelope by a trans-membrane spanning stator. The central part of this stator, TssM, is
a 1129-amino-acid protein anchored in the inner membrane that binds to the TssJ outer
membrane lipoprotein. In this study, we have raised camelid antibodies against the purified
TssM periplasmic domain. We report the crystal structure of two specific nanobodies that
bind to TssM in the nanomolar range. Interestingly, the most potent nanobody, nb25, com-
petes with the TssJ lipoprotein for TssM binding in vitro suggesting that TssJ and the nb25
CDR3 loop share the same TssM binding site or causes a steric hindrance preventing
TssM-TssJ complex formation. Indeed, periplasmic production of the nanobodies displacing
the TssM-TssJ interaction inhibits the T6SS function in vivo. This study illustrates the power
of nanobodies to specifically target and inhibit bacterial secretion systems.
Introduction
The type VI secretion system (T6SS) is a machinery widespread in Gram-negative bacteria and
dedicated to the delivery of toxins in bacterial and eukaryotic host cells. By its anti-bacterial an-
tagonistic action, the T6SS is one of the main players in the bacterial warfare for the access to
nutrients and for colonization of the ecological niche [1, 2]. The T6SS assembles from 13
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conserved components. Architecturally, the T6SS can be seen as a micrometer-long syringe an-
chored to the cell membrane by a trans-envelope complex [3–6]. The phage tail-related sy-
ringe-like tubular structure is composed of an internal tube tipped by a spike-like complex,
wrapped by a contractile sheath and tethered to the membrane through contacts with compo-
nents of a trans-envelope multiprotein complex [6, 7]. This membrane-associated complex is
composed of the TssL and TssM inner membrane proteins and of the TssJ outer membrane li-
poprotein [8–13]. The TssM and TssL proteins interact and stabilize each other and share ho-
mologies with the Type IVb secretion system IcmF and DotU subunits respectively [12, 14,
15]. In enteroaggregative Escherichia coli (EAEC), TssM (accession number: EC042_4539;
gene ID: 387609960) is a 1129-amino-acid protein anchored to the inner membrane by three
transmembrane helices and bearing a large ~ 750 amino-acid periplasmic domain (amino-
acids 386–1129). The C-terminal extremity of the TssM periplasmic domain interacts with the
L1-2 loop of the TssJ lipoprotein with a KD of 2–4 μM [11]. By combining interactions with
inner membrane and outer membrane-associated components, the TssM protein crosses the
cell envelope and is therefore central to the T6SS membrane complex.
Although the EAEC TssM periplasmic domain purified readily, we did not succeed to gain
structural information [11]. One of the most efficient approaches to improve the crystallization
process is to use co-crystallization of the protein of interest with cognate camelid nanobodies.
Camelid (llamas, dromaderies and alpacas) antibodies differ from classical antibodies as they
only associate two heavy-chains, lacking the CH1 domain and terminated by monomeric vari-
able antigen-binding VHH domains called nanobodies [16, 17, 18]. By contrast to the conven-
tional immunoglobulin domains, these single-domain VHH antibodies are highly convenient:
in addition to be the smallest antibodies, they are easy to produce in the E. coli periplasm [19].
Therefore, they have remarkable potential in the biotechnology and bio-pharmaceutical fields
[18, 20, 21]. More important for structural biologists, they also demonstrated their efficiency to
improve protein solubility and facilitating crystallization when complexed with the protein of
interest [19], in particular for membrane-associated or flexible proteins [22, 23, 24, 25, 26]. Fi-
nally, due to their high affinity and selectivity and their small size, nanobodies are excellent en-
zymes and receptors inhibitors and can be used for functional studies.
To gain further information on the EAEC TssM protein, the purified TssM periplasmic do-
main was used for llama immunization. Here we report the selection and the structural analysis
of two specific nanobodies. These antibodies bind to the TssM periplasmic domain with a KD
in the nanomolar range. One of these nanobodies disrupts the TssM-TssJ interaction in vitro
and prevents the proper function of the T6SS apparatus.
Results and Discussion
Selection and crystal structures of TssM-specific nanobodies
Nanobodies were raised by immunization of llamas with the purified periplasmic domain of
the EAEC TssM protein (TssMp). Three strong TssMp binders were identified from the im-
mune library by three rounds of panning using phage display coupled to ELISA. Two nanobo-
dies, called nb02 and nb25, were selected for further studies based on their high affinity for
TssM and on their amino-acid differences in the variable regions, suggesting they bind distinct
regions of TssMp (Fig. 1A). The third nanobody, nb42, is very similar to nb25, and was not re-
tained for the structural studies. The two selected nanobodies, nb02 and nb25, sharing 77% se-
quence identity, were produced in the periplasm of E. coli, purified to homogeneity and
concentrated to 10 mg/ml. Both nb02 and nb25 behaved as monomers in size-exclusion chro-
matography and both crystallized readily, allowing to solve their three-dimensional structures
by molecular replacement (Fig. 1B and 1C). Crystal structures were refined to 1.7 Å and 1. 38
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Å resolution with R/Rf values of 25.1/20.5% and 19.1/19.8%, respectively (Table 1). Overall, the
two structures (nb02, PDB 4QLR; nb25, PDB 4QGY) are very similar. The superimposed struc-
tures of nb02 and nb25 differ by a rmsd of 1.13 Å on 118 aligned residues (Fig. 1D). However,
despite identical lengths, the conformations of the nb02 and nb25 CDR1 and CDR2 regions
differ significantly (Fig. 1D). More importantly, large differences can be observed on the CDR3
regions, notably in terms of size (14-residue long for nb02, 19-residue long for nb25). Notewor-
thy, the nb25 CDR3 region is stabilized by a disulfide bridge between Cys-106 and CDR2 Cys-
50 and extends out of the nanobody core, providing a large putative binding area for the anti-
gen (Fig. 1C).
Nanobodies bind TssM with nanomolar affinities
To gain further information on the nanobodies, the strengths of their interactions with TssMp
were measured by surface plasmon resonance (SPR). Nb02, nb25 and the nb25 variant nb42
were covalently coupled to the CHIP and sensorgrams were recorded after injection of the pu-
rified TssMp fragment in the microfluidic channel (Fig. 2). Analysis of the SPR curves indicate
that nb02, nb25 and nb42 bind to TssMp with KD values of 66.8±2 nM, 1.61± 0.1 nM and
1.76± 0.1 nM, respectively (Table 2).
Nb25 interferes with TssJ binding to TssM
We previously reported that TssJ binds to TssMp with a KD value of 2–4 μM. This interaction
is mediated by the L1-2 loop of TssJ and is essential for the proper function of the T6SS [11].
Fig 1. Structure of the anti-TssM nanobodies. (A) Sequence alignment of nanobodies nb02, nb25 and
nb42. Identical amino-acids are in white and underlined in red, similar amino-acids are colored in red,
different amino-acids are in black. The CDR1, CDR2 and CDR3 are highlighted in blue, green and yellow,
respectively. The green numbers (1 or 2) below the sequence indicate cysteine residues involved in
disulphide bridges SS1 (1, Cys22 and Cys96) and SS2 (2, Cys50 and Cys106) disulphide bridges formation.
Crystal structure of nanobodies nb02 (B) and nb25 (C), represented as ribbons and colored in rainbowmode.
(D) Superimposition of the structures of nb02 (grey) and nb25 (rainbow color). The locations of the CDR1,
CDR2 and CDR3 variable regions are indicated as well as the positions of disulphide bridges (SS1 and SS2).
doi:10.1371/journal.pone.0122187.g001
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Based on these results, we hypothesized that the TssJ L1-2 loop will contact a crevice within
TssM [11]. Because nanobodies are known to target enzymatic sites or crevices [27], we sought
to determine whether the nanobodies and TssJ share the same TssM-binding site. We therefore
performed Bilayer interferometry (BLI) competition experiments between the nanobodies and
TssJ on TssMp. The TssJ protein (devoid of its N-terminal Cys acylation residue) was biotiny-
lated and coupled to the streptavidine BLI chip. The chip was immersed on solution containing
TssMp-nanobody complexes. Due to the 50- to 1000-fold magnitude differences between the
KDs of TssJ and that of the nanobodies to TssMp, we expected that the occupation of the TssJ
binding site by the nanobody would prevent TssMp binding to TssJ. Fig. 3 shows that the
TssMp-nb02 complex can readily interact with TssJ. The formation of the nb02-TssMp-TssJ
ternary complex demonstrates that TssJ and nb02 bind TssM differently. By contrast, the
TssMp-nb25 complex does not bind TssJ demonstrating that nb25 interferes with TssJ binding
on TssMp. This result suggests that nb25 and TssJ share the same TssM binding site or that
nb25 binding on TssMp causes steric hindrance preventing TssJ binding.
Nb25 disrupts the TssMp-TssJ interaction in vitro
We hypothesized that if nb25 and TssJ share the same TssM binding site, nb25 should disrupt
the TssM-TssJ complex. We therefore analyzed the effect of nb25 on the stability of the
TssM-TssJ complex. Competition experiments were performed by incubating the purified
TssMp-TssJ complex with an excess of nb25, prior to analysis by gel filtration. Three peaks
were observed on the chromatogram (Fig. 4). Analysis of the peaks by SDS-PAGE (Fig. 4,
inset) showed that peak 1 (~ 90 kDa) contained TssMp and nb25 (theoretical weight of the
TssMp-nb25 complex = 98 kDa), while peak 2 (~ 18 kDa) contained TssJ (theoretical
Table 1. Data collection and refinement statistics for the nb02 and nb25 anti-TssM nanobodies.
DATA COLLECTION nb02 (PDB:4QLR) nb25 (PDB:4QGY)
Diffraction source ESRF Soleil PX1
Detector Pilatus 6M Pilatus 6M
Space group P 21 C2221
Cell dimensions (Å,°) a = 50.0, b = 48.6, c = 52.9 Å3 β = 118.8° a = 52.0, b = 70.9, c = 145.7 Å3
Resolution rangea (Å) 50–1.70 (1.76–1.70) 50–1.38 (1.42–1.38)
R-mergea (%) 7.0 (52) 3.1 (70)
CC(1/2)a (%) 99.7 (73.1) 100 (85)
Mean((I)/sd(I))a 9.6 (1.7) 29 (2.6)
Total number of reﬂectionsa 62041 (5333) 395611 (25318)
Number of unique reﬂectionsa 23496 (2222) 55440 (3886)
Completenessa (%) 94.3 (90.3) 99.6 (95)
Multiplicitya 2.64 (2.4) 7.1 (6.5)
REFINEMENT
Resolutiona (Å) 44.1–1.7 (1.78–1.7) 20–1.38 (1.42–1.38)
Nr of reﬂectionsa 23498 (2742) 55416 (3814)
Nr protein / water 1931 / 211 1918 / 309
Nr test set reﬂections 1201 2813
Rwork/Rfree
a (%) 20.5/25.1 (24.0/25.4) 19.1/19.8 (32.2/36.7)
r.m.s.d.bonds (Å) / angles (°) 0.01 / 1.02 0.01 / 1.09
B-wilson / B-average 21.0 / 23.6 20.3 / 24.8
a numbers in brackets refer to the highest resolution bin.
doi:10.1371/journal.pone.0122187.t001
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Fig 2. Nanobodies nb02 and nb25 bind TssMpwith nanomolar affinity. Surface Plasmon Resonance recordings representing binding and release of the
purified periplasmic domain of TssM (from bottom to top: 1.95, 3.9, 7.8, 15.6, 31.25, 62.5, 125 and 250 nM) to nanobody nb02 (A), nb25 (B) or nb42 (C)
immobilized on the Chip. The variation of the Surface Plasmon Resonance (shown as the experimental and fitting curves) is reported on the y axis (in
arbitrary unit, RU) plotted versus the reaction time on the x axis (in sec.). The apparent KDs are indicated on the top of each graph. The kinetic and
thermodynamic parameters are indicated in Table 2.
doi:10.1371/journal.pone.0122187.g002




-1) KD (nM) Rmax
nb02 6.02 105 402 10-4 66.8 ± 2.5 734
nb25 3.5 105 5.6 10-4 1.61 ± 0.05 1165
nb42 2.04 105 3.6 10-4 1.76 ± 0.08 3155
doi:10.1371/journal.pone.0122187.t002
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Fig 3. Binding of TssMp:nanobody complexes to TssJ. Bilayer interferometry recordings representing
binding of TssMp alone (blue) or the TssMp:nb02 (red) or TssMp:nb25 (green) complexes to chip coupled to
TssJ. The response (in nm) is plotted versus the time (in sec.). The absence of response in the green
sensorgram indicates that nb25 prevents attachment of TssMp to TssJ.
doi:10.1371/journal.pone.0122187.g003
Fig 4. Nanobody nb25 disrupts the TssMp:TssJ complex. The pre-formed TssM-TssJ complex was analyzed by size exclusion chromatography before
(dash line) and after incubation with an excess of nb25 (plain line). The composition of the different complexes, eluting at different volumes, was analysed by
SDS-PAGE and Coomassie blue staining (inset). The fractions corresponding to peak 1–3 are indicated on the top. The molecular masses of the protein
markers (in kDa) are indicated on the left. According to the calibration of the column, the apparent molecular weights for peak 1 (9.72 ml), peak 2 (13.02 ml)
and peak 3 (14.43 ml) are about 90, 18 and 14 kDa, respectively. The faint band at the position of TssMp in peaks 2 and 3 of the SDS gel arise from
contamination by the large main TssMp peak 1.
doi:10.1371/journal.pone.0122187.g004
Nanobody-Mediated T6SS Inhibition
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Fig 5. TssM-specific nanobodies nb25 and nb42 specifically affect T6SS function. (A) Hcp release assay. HA-epitope-tagged Hcp (HcpHA) release was
assessed by separating whole cells (C) and supernatant (S) fractions from wild-type (WT), ΔtssM cells or WT cells producing 6His-tagged nanobodies as
indicated. 2×108 cells and the TCA-precipitated material of the supernatant from 5×108 cells were loaded on a 12.5%-acrylamide SDS-PAGE and the
nanobodies (lower panel), Hcp (middle panel) and periplasmic TolB (cell integrity control, upper panel) proteins were immunodetected using anti-5His, anti-
HA and anti-TolB antibodies respectively. (B) Anti-bacterial assay. The Sci-1 T6SS-dependent anti-bacterial activity was assessed by mixing prey cells
(W3110 gfp+, kanR) with the indicated attacker cell (K-12, W3110; WT, EAEC 17–2; ΔtssM, 17–2ΔtssM or WT cells producing the indicated nanobody) for 16
hours at 37°C in sci-1-inducing medium (SIM). The recovered fluorescent level (in arbitrary units) is shown in the upper graph (mean of fluorescence levels
per OD600nm obtained from four independent experiments). The number of recovered viable prey cells, expressed in colony forming unit (cfu) is shown in the
lower graph (the triangles indicate values from four independent assays, and the average is indicated by the bar).
doi:10.1371/journal.pone.0122187.g005
Nanobody-Mediated T6SS Inhibition
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weight = 17 kDa) and peak 3 (~ 14 kDa), the excess of nb25 (theoretical weight = 14 kDa).
These data confirm that nb25 binds to TssMp and chases TssJ from the pre-assembled TssMp-
TssJ complex.
Nb25 prevents formation of a functional T6SS
The TssM-TssJ interaction was previously shown to be indispensable for the proper function
of the Type VI secretion apparatus in enteroaggregative E. coli [11]. As nb25 (and nb42) com-
pete with TssJ for TssM binding in vitro, we wondered whether these nanobodies would dis-
rupt the TssM-TssJ interaction in vivo. The vectors allowing the periplasmic production of the
nb02, nb25 and nb42 nanobodies, as well as a control nanobody (a nanobody targeting the Lac-
tococcus lactis phage 1358 receptor binding protein) were introduced into the wild-type EAEC
strain 17–2. The function of the T6SS was assessed by the Hcp1 release assay and by the Sci1--
dependent antibacterial activity. As shown in Fig. 5, the control nanobody and nb02 had no—
or little—effect on the function of the T6SS as 17–2 cells producing nb02 released the Hcp1
protein and retained anti-bacterial activities at levels comparable to that of wild-type 17–2
cells. By contrast, the periplasmic production of nb25 and nb42 inhibited the function of the
T6SS as (i) no Hcp1 was found in the culture supernatant of 17–2 cells producing these VHHs
and (ii) these cells did not have any growth advantage when co-cultured with E. coli K-12 cells.
Taken together, these results suggest that disruption of the TssM-TssJ interaction prevents the
formation of a functional Type VI secretion apparatus in EAEC.
Concluding Remarks
In this study, we raised and selected two camelid variable fragments of heavy-chain antibodies
specific to the EAEC T6SS TssM periplasmic domain. Although this strategy was originally ini-
tiated to help the crystallization of the TssM protein, we used here these nanobodies to gain
functional information on the assembly of the T6SS apparatus. We showed that the two select-
ed nanobodies bind TssMp with nanomolar affinities. These values are in agreement with the
affinities of nanobodies, including that targeting the Salmonella Typhimurium actin ADP-
ribosylating toxin or the Pseudomonas aeruginosa flagellin [28, 29]. BLI and gel filtration ex-
periments showed that nb25 is a competitor of TssJ in vitro, suggesting that nb25 binds at—or
close to—the TssJ binding site on TssMp or at least causes a steric hindrance or a TssM confor-
mational change preventing TssM-TssJ complex formation. Due to the variability of the CDR3
protruding loop and the observation that nanobodies are often targeting crevices [27], we hy-
pothesize that the nb25 CDR3 loop mediates the interaction with a crevice in TssM, such as the
TssJ L1-2 loop does [11]. Significant sequence differences occur in the CDR1 and CDR2 of
nb25 and nb42, while the CDR3 are identical. This observation is in line with our hypothesis of
CDR3 binding to the TssJ binding site of TssM. Sequence alignment between the TssJ LI-2
loop and the CDR1, CDR2 and CDR3 of nb25 shows that, except an A-X-G-I motif, very limit-
ed similarities exist between TssJ and CDR3. However, the TssJ L1-2 loop being elongated
whereas the CDR3 having a compact fold, no structural conservation is observed between
these loops suggesting that TssJ L1-2 and nb25/nb42 CDR3 do not bind identically to TssM, al-
though we cannot exclude loop rearrangements upon binding. In view of these results, the co-
crystallization between TssMp and nb25 is therefore essential, not only to gain structural infor-
mation on TssM but also to identify the nb25-binding site and to test whether this region is
also responsible for making contacts with the TssJ L1-2 loop. Interestingly, the use of nanobo-
dies for co-crystallization was successful in this specific case as we recently obtained co-crystals
between a fragment of the periplasmic domain of TssM and nb25 and performed a preliminary
X-ray diffraction analysis [30].
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By contrast, although nb02 has strong affinity for TssM, we showed that nb02 does not
compete with TssJ for TssM binding in vitro. Because of the formation of an nb02-TssMp-TssJ
ternary complex, nb02 is an interesting tool to assist the crystallization of the TssMp-TssJ com-
plex. Hcp release and growth competition assays showed that nb02 has no inhibitory effect in
vivo. Therefore, defining the site of binding of nb02 on TssM is also interesting as this nano-
body targets a region that is not critical for the assembly of the T6SS membrane complex.
Nanobodies targeting bacterial multi-protein complexes or toxins have already been re-
ported. For examples, specific nanobodies to the Vibrio Type II secretion (T2SS) GspD secretin
and EspI/J pseudopilin complex have been selected and used for structural studies but their ef-
fect on the assembly of the T2SS in vivo has not been addressed [31]. By contrast, nanobodies
interacting with the P. aeruginosa or Campylobacter jejuni flagellin decrease the swimming rate
and biofilm formation of these strains [29, 32]. Similarly, nanobodies that bind to and interfere
with the catalytic site of the S. Typhimurium ADP-ribosylation toxin diminish the cytotoxicity
in vivo [28]. Our study not only paves the way to the structural characterization of the TssM
periplasmic domain and of the TssMp-TssJ complex, but also demonstrates that nanobodies
can be used to inhibit the assembly of the T6SS or of secretion systems in general with the goal
to diminish or abolish the fitness or the virulence of bacterial pathogens in their
ecological niche.
Materials and Methods
Bacterial strains, growth conditions and chemicals
The entero-aggregative E. coli EAEC strain 17–2 and its ΔtssM isogenic derivative [10] were
used for this study. The E. coli K-12 WK6 strain was used for nanobody production. The E. coli
K-12 W3110 strain carrying the pUA66-rrnB plasmid (gfp under the control of the constitutive
rrnB ribosomal promoter, specifying strong and constitutive fluorescence, and kanamycin re-
sistance [33]) was used as prey in antibacterial competition experiments. Strains were routinely
grown in lysogeny broth (LB) or Terrific broth at 37°C, with aeration. For antibacterial compe-
tition assays, cells were grown in sci-1-inducing medium (SIM: M9 minimal medium, glycerol
0.2%, vitamin B1 1 μg/ml, casaminoacids 100 μg/ml, LB 10%, supplemented or not with bac-
toagar 1.5%). Plasmids were maintained by the addition of ampicillin (200 μg/mL) or kanamy-
cin (50 μg/mL). The expression of the nanobody constructs cloned into pHEN6 vector
derivatives was induced by the addition of isopropyl-β-thio-galactoside (IPTG).
Generation of llama nanobodies against TssM
The periplasmic domain of TssM (amino-acids 386–1129; TssMp) was produced and purified
as described previously [11]. Four injections of 1 mg of recombinant TssMp (in Tris-HCl 20
mM (pH 8.0), NaCl 150 mM) were performed subcutaneously with two weeks intervals fol-
lowed by a fifth injection one month later in two llamas (Lama glama) (Capralogics Inc., Hard-
wick, MA 01037 USA). Lymphocytes were isolated from blood sample obtained 1 week after
the last immunization. cDNA was synthesized from purified total RNA by reverse transcrip-
tion. The cDNA was used as template for PCR amplification to amplify sequences correspond-
ing to the variables domains of the heavy-chain antibodies. PCR fragments were cloned into
the phagemid vector pHEN4 [34] to create a nanobody phage display library. Selection and
screening of nanobodies were performed as previously published [35]. Three rounds of pan-
ning resulted in the isolation of TssMp-specific binders. Nanobodies nb02, nb25 and its variant
nb42 were selected, sequenced and cloned into the pHEN6 expression vector downstream the
pelB signal peptide and fused to a C-terminal 6×His tag [36].
Nanobody-Mediated T6SS Inhibition
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Purification of nanobodies
E. coliWK6 cells carrying the pHEN6 derivatives were grown at 37°C in Terrific Broth medium
containing 0.1% glucose and ampicillin to an optical density (OD600nm) ~ 0.8. The expression
of the nanobody was induced by the addition of 1 mM IPTG and incubation for 16 hours at
28°C. The periplasmic fraction containing the nanobodies was prepared by osmotic shock. The
His-tail-containing fusion proteins were purified by immobilized metal affinity chromatogra-
phy on a 5-mL Ni-NTA column equilibrated in 50 mMNa/K phosphate (pH 8.0), 300 mM
NaCl, 10% glycerol. Nanobodies were eluted in 250mM imidazole and concentrated (Amicon-
Ultra 10-kDa cut-off) prior to be loaded on a HiLoad 16/60 Superdex 75 gel filtration column
equilibrated in 20 mM Tris–HCl (pH 8.0), 150 mMNaCl.
Nanobodies structure determination
Crystallization screening experiments were performed with several commercial kits. The nano-
drop crystallization experiments were performed in Greiner plates. The reservoirs of the Grei-
ner plates were filled up using a TECAN pipetting robot, while the nano-L drops were dis-
pensed by a Mosquito robot using nano-crystallization protocols [37]. All crystallization
experiments were performed at 293K. Nanobody nb02 crystallized at 15 mg/mL in 100 mM so-
dium cacodylate (pH 6.5), 25% w/v PEG 8000, 200 mM (NH4)2SO4. Nanobody nb25 crystal-
lized at 15 mg/mL in 100 mM CHES (pH 10), 1 M K/Na tartrate, 200 mM Li2SO4. Crystals
were mounted in loops and soaked in their crystallization solution supplemented by 4M
TMAO before cryocooling.
Data collection of nb02 and nb25 were performed at synchrotrons ESRF (Grenoble, France)
beamline ID29 and Soleil PX1 (saint-Aubin, France), respectively (Table 1). Data were inte-
grated with XDSME and scaled with XSCALE. The nb02 crystals belong to space-group P21,
with cell dimensions a = 50.0, b = 48.6, c = 52.9 Å3, β = 118.8°. Two molecules in the symmetric
unit yield a Vm value of 2.0 Å3/Da and 38% solvent. The nb25 crystals belong to space-group
C2221, with cell dimensions a = 52.0, b = 70. 9, c = 145.7 Å
3. Two molecules in the asymmetric
unit yielded a Vm value of 2.20 Å3/Da and 45% solvent. These crystals diffracted to 1.70 Å and
1.38 Å resolution, respectively (Table 1). Molecular replacement was performed using MOL-
REP [38] and nanobody structures with high sequence similarity to nb25 (PDB: 4KRP) and
nb02 (PDB: 4HEP) as starting models. Refinement was performed using autoBUSTER [39] al-
ternated with rebuilding with COOT [40].
Accession numbers
Atomic coordinates have been deposited in the Protein Data Bank as identifiers 4QLR (nb02)
and 4QGY (nb25).
Surface Plasmon Resonance (SPR) measurements
The interaction between TssMp and nanobodies was tested by SPR using a Biacore X100 (GE
healthcare). Nb02, nb25 and nb42 were covalently linked to a CM5 chip and different concen-
trations of TssMp were injected in the microfluidic channel. Regeneration was achieved by the
injection of glycine-HCl (pH 2.5) buffer. The KD values were calculated by the multi-cycle ki-
netics method (Biacore, GE-healthcare).
Biolayer interferometry (BLI)
TssJ was first biotinylated using the EZ-Link NHS-PEG4-Biotin kit (Perbio Science, France).
The reaction was stopped by removing the excess of the biotin using a Zeba Spin Desalting
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column (Perbio Science, France). BLI studies were performed in black 96-well plates (Greiner)
at 25°C using an OctetRed96 (ForteBio, USA). Streptavidin biosensor tips (ForteBio, USA)
were first hydrated with 0.2 ml Kinetic buffer (KB, ForteBio, USA) for 20 min and then loaded
with biotinylated TssJ (10 μg/ml in KB). The association of TssJ with TssM (300 nM) was mon-
itored for 200 sec, as well as the dissociation in KB. For TssM/nanobody competition experi-
ments, nb02 or nb05 nanobodies were used at a TssJ:nanobody ratio of 3:1.
Size Exclusion Chromatography (SEC)
Size exclusion chromatography was performed on an Alliance 2695 HPLC system (Waters)
using a pre-calibrated Superdex 75 10/300 GL gel filtration column run in 20 mM Tris-HCl
(pH 8.0), 100 mM NaCl at 0.5 mL/min.
Hcp release assay
The expression of the nanobody constructs cloned into pHEN6 vector derivatives was induced
by the addition of 0.5 mM isopropyl-β-thio-galactoside (IPTG) for 45 min. Supernatant and
cell fractions were separated as previously described [12, 13] with the addition of the iron che-
lator 2,2’-dipyridyl (125 μM final concentration) to the culture medium 30 min before harvest-
ing the cells to induce the expression of the sci-1 T6SS [41]. Briefly, 2 × 109 cells producing HA
epitope-tagged Hcp (from plasmid pOK-HcpHA; [10]) and the 6×His-tagged nanobody con-
structs were harvested and collected by centrifugation at 2,000 × g for 5 min. The supernatant
fraction was then subjected to a second low-speed centrifugation and then at 16,000 × g for 15
min. The supernatant was filtered on sterile polyester membranes with a pore size of 0.2 μm
(membrex 25 PET, membraPure GmbH) before overnight precipitation with trichloroacetic
acid (TCA) 15% on ice. Cells and precipitated supernatants were resuspended in loading buffer
and analyzed by Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
and immunoblotting with the anti-HA antibody. As control for cell lysis, Western blots were
probed with antibodies raised against the periplasmic TolB protein. The production of the
nanobodies was verified by immunoblotting with the anti-5His antibody.
Sci-1-dependent antibacterial assay
The antibacterial competition growth assay was performed as described for the studies on the
Citrobacter rodentium and EAEC Sci-2 T6SSs [42, 43] with modifications. The wild-type E. coli
strain W3110 bearing the pUA66-rrnB plasmid KanR [33] was used as prey in the competition
assay. The pUA66-rrnB plasmid provides a strong constitutive green fluorescent (GFP+) phe-
notype. Attacker and prey cells were grown for 16 hours in LB medium, then diluted 100-fold
in SIM. Once the culture reached an OD600nm = 0.8, the cells were harvested and resuspended
to an OD600nm of 0.5 into SIM. For the attacker cells, the expression of the VHH-encoding
genes was induced for 45min. with 0.5 mM IPTG prior to cell harvest. Attacker and prey cells
were mixed to a 4:1 ratio and 25-μl drops of the mixture were spotted in triplicate onto a pre-
warmed dry SIM agar plate supplemented with 0.5 mM IPTG. After overnight incubation at
30°C, the bacterial spots were cut off, and cells were resuspended in LB to an OD600nm of 0.5.
Triplicates of 150 μl were transferred into wells of a black 96-well plate (Greiner), and the ab-
sorbance at 600 nm and fluorescence (excitation, 485 nm; emission, 530 nm) were measured
with a Tecan Infinite M200 microplate reader. The relative fluorescence was expressed as the
intensity of fluorescence divided by the absorbance at 600 nm, after subtracting the values of a
blank sample. For enumeration of viable prey cells, bacterial suspensions recovered from the
spots were serially diluted and spotted onto selective LB agar plates supplemented with kana-
mycin (for the E. coli prey cells).
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Miscellaneous
SDS-Polyacrylamide gel electrophoresis was performed using standard protocols. For immu-
nostaining, proteins were transferred onto nitrocellulose membranes, and immunoblots were
probed with primary antibodies, and goat secondary antibodies coupled to alkaline phospha-
tase, and developed in alkaline buffer in presence of 5-bromo-4-chloro-3-indolylphosphate
and nitroblue tetrazolium. The anti-TolB polyclonal antibodies are from our laboratory collec-
tion, while the anti-HA (3F10 clone, Roche), the anti-5His (Qiagen) monoclonal antibodies
and alkaline phosphatase-conjugated goat anti-rabbit, mouse, or rat secondary antibodies
(Millipore) have been purchased as indicated.
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